Bill Aliski
Director/Board Member chez X4 PHARMACEUTICALS, INC.
Fortune : 71 817 $ au 31/03/2024
Profil
William E.
Aliski is an Independent Director at X4 Pharmaceuticals, Inc. He previously served as an Independent Director at Ultragenyx Pharmaceutical, Inc. from 2011 to 2022, and as a Director at Scioderm, Inc., Beacon Therapeutics (USA), Inc., Edimer Pharmaceuticals, Inc., and Transkaryotic Therapies, Inc. He was also the Vice President-Commercial Operations at Transkaryotic Therapies, Inc. and the Vice President-Patient & Product Services at Genzyme Corp.
Additionally, he was the Chief Commercial Officer & Senior Vice President at FoldRx.
Pharmaceuticals LLC from 2009 to 2011.
Aliski holds a graduate degree from Boston College and a graduate degree from Harvard Kennedy School of Government.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
X4 PHARMACEUTICALS, INC.
0,03% | 13/06/2023 | 51 667 ( 0,03% ) | 71 817 $ | 31/03/2024 |
Postes actifs de Bill Aliski
| Sociétés | Poste | Début |
|---|---|---|
| X4 PHARMACEUTICALS, INC. | Director/Board Member | 18/09/2019 |
Anciens postes connus de Bill Aliski
| Sociétés | Poste | Fin |
|---|---|---|
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Director/Board Member | 01/12/2022 |
| ULTRAGENYX PHARMACEUTICAL INC. | Director/Board Member | 24/06/2022 |
FoldRx Pharmaceuticals LLC
 FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/03/2011 |
Simon-Kucher & Partners GmbH
 Simon-Kucher & Partners GmbH Miscellaneous Commercial ServicesCommercial Services Simon-Kucher & Partners GmbH provides strategy, marketing and pricing services. It offers consulting services in the areas of setting and managing prices, strategic development, product and market strategy, marketing leadership, and sales execution. The firm has offices in Amsterdam, Bonn, Boston, Brussels, Cologne, Frankfurt, London, Luxembourg, Barcelona, Madrid, Milan, Moscow, Munich, New York, Paris, San Francisco, Tokyo, Vienna, Warsaw, Beijing, Singapore, Sydney and Zurich. The company was founded by Hermann Simon, Eckhard Kucher and Karl-Heinz Sebastian in 1985 and is headquartered in Bonn, Germany. | Director/Board Member | 01/06/2009 |
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/01/2008 |
Formation de Bill Aliski
| Boston College | Graduate Degree |
| Harvard Kennedy School of Government | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
FoldRx Pharmaceuticals LLC
FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA. | Health Technology |
Scioderm, Inc.
 Scioderm, Inc. BiotechnologyHealth Technology Scioderm, Inc. engages in the development of innovative therapies for areas of high unmet need, including orphan products. The company was founded by Robert Ryan and Robert John Coull in 2012 and is headquartered in Durham, NC. | Health Technology |
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
Simon-Kucher & Partners GmbH
Simon-Kucher & Partners GmbH Miscellaneous Commercial ServicesCommercial Services Simon-Kucher & Partners GmbH provides strategy, marketing and pricing services. It offers consulting services in the areas of setting and managing prices, strategic development, product and market strategy, marketing leadership, and sales execution. The firm has offices in Amsterdam, Bonn, Boston, Brussels, Cologne, Frankfurt, London, Luxembourg, Barcelona, Madrid, Milan, Moscow, Munich, New York, Paris, San Francisco, Tokyo, Vienna, Warsaw, Beijing, Singapore, Sydney and Zurich. The company was founded by Hermann Simon, Eckhard Kucher and Karl-Heinz Sebastian in 1985 and is headquartered in Bonn, Germany. | Commercial Services |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Health Technology |
